{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001381846,0.0003767898,0.00265922,0.0002218187,0.0002139076,0.00006149373,0.00096286,0.0002048342,0.0003080319],"category_scores_gemma":[0.001222085,0.0002494632,0.0001305151,0.0005893558,0.0006024683,0.0002198232,0.0002584392,0.0006432859,0.000004721359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001919983,"about_ca_system_score_gemma":0.001750941,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02726557,"about_ca_topic_score_gemma":0.05546609,"domain_scores_codex":[0.9959414,0.0009745749,0.0008918167,0.0007632762,0.00068285,0.0007461075],"domain_scores_gemma":[0.9955316,0.001432156,0.0008806374,0.001299061,0.0006509746,0.0002055839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.964545,0.003029333,0.009050699,0.0000287089,0.002948453,0.0001745375,0.003082528,0.0001544666,0.0003237694,0.0000101823,0.0004710185,0.01618137],"study_design_scores_gemma":[0.7859724,0.012272,0.1976468,0.0003198659,0.001991476,0.000002157099,0.000215502,0.0009587774,0.0001361228,0.000008775104,0.0002549344,0.0002211817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849455,0.0001344886,0.00001642962,0.00258871,0.0003898984,0.004695588,0.0046466,0.00002457251,0.002558195],"genre_scores_gemma":[0.996963,0.0003407483,0.0004181742,0.0001232943,0.0003924428,0.0006468726,0.0007915624,0.00004514403,0.0002787554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1885961,"threshold_uncertainty_score":0.9999958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1471450445887598,"score_gpt":0.4395473762209945,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}